Breaking Finance News

Sarepta Therapeutics Inc (NASDAQ:SRPT) has been upgraded to Neutral in a report by SunTrust Banks Inc. today.

SunTrust Banks Inc. has upgraded Sarepta Therapeutics Inc(NASDAQ:SRPT) to Neutral in a statement released on 9/14/2016.

Previously on Friday July 22 2016, Needham released a statement about Sarepta Therapeutics Inc(NASDAQ:SRPT) bumped the target price from $20.00 to $26.00. At the time, this indicated a possible upside of 0.15%.

Only yesterday Sarepta Therapeutics Inc (NASDAQ:SRPT) traded 91.30% higher at $51.30. SRPT’s 50-day moving average is $26.16 and its 200-day moving average is $20.47. With the last stock price close up 163.13% relative to the 200-day average, compared to the S&P 500 Index which has decreased -0.01% over the same time period. 29,541,278 shares of Sarepta Therapeutics Inc exchanged hands, up from ann avg. volume of 2,328,380.

See Graph Below:

Sarepta Therapeutics Inc (NASDAQ:SRPT)

With a market capitalization of $0.0, Sarepta Therapeutics Inc has a one-year low of $8.00 and a one-year high of $56.18 with a P/E ratio of 0.

Also covering Sarepta Therapeutics Inc’s stock price target, a total of 13 brokers have issued a report on the company. The one year target stock price is $20.77 with three firms rating the stock a strong buy, one firm rating the stock a buy, five analyts rating the stock a hold, four firms rating the stock to underperform, and lastly one firmrating the stock as sell.

About Sarepta Therapeutics Inc (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *